Big Pharma, Big Money: Johnson&Johnson, Pfizer, Bayer, Novartis in Digital Health

Big Pharma, Big Money: Johnson&Johnson, Pfizer, Bayer, Novartis in Digital Health

Posted Oct 12, 2021 from

In a recent series of articles, we explored the latest moves of Tech Giants like Amazon, NVIDIA and Microsoft in the field of digital health. Analysing these recent developments can give us a better idea regarding where they are focusing the efforts, and how it might shape the future path of healthcare. 

But equally, if not more, strong players in this field are pharmaceutical giants, as their resources and influence can significantly shape or alter the course of this path. As such, we are kickstarting a new series of articles focusing on the digital health efforts of 14 global pharma companies. While those heavyweights are involved in a plethora of healthcare-related projects from vaccine development to clinical trials, we will specifically focus on digital health.

In the first article to the series, we will explore developments coming from pharma giants Johnson & Johnson, Pfizer, Bayer and Novartis. Let’s take a closer look!


See Topics

See Also

Next Article